[en] The aim of our work was to test the usability of fecal calprotectin (FC) home-based test in inflammatory bowel disease (IBD) patients. METHODS: IBD patients were prospectively recruited. They had to measure FC with a dedicated tool and smartphone application, 5 times at two weeks intervals over an 8 weeks period. They had to fill in a usability questionnaire at the first and the last FC measurement. A System Usability Scale (SUS: 0-100) and the Global Score of Usability (GSU: 0-85) were calculated. FC was also centrally measured by ELISA. RESULTS: Fifty-eight patients were recruited. Forty-two performed at least one FC measurement and 27 performed all the FC requested measurements. The median (IQR) SUS (0-100) at the first and last use were 85 (78-90) and 81 (70-88), respectively; the median (IQR) GSU (0-85) at the first and last use were 74 (69-80) and 77 (68-83), respectively. Adherence to the planned measurements and usability of the tool were higher in females and in less severe disease. The intra-class correlation coefficient between home-based and centrally measured FC was 0.88. CONCLUSION: The adherence to home-based measurement of FC was fair. Usability scores for the home-based test were high. There was a good correlation with the centrally measured FC by ELISA.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Bello, Caroline
Roseth, Arne
Guardiola, Jordi
REENAERS, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
Ruiz-Cerulla, Alexandra
VAN KEMSEKE, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
Arajol, Claudia
Reinhard, Christian
SEIDEL, Laurence ; Centre Hospitalier Universitaire de Liège - CHU > Service des informations médico économiques (SIME)
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients.
Annese, V., Daperno, M., Rutter, M.D., et al. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 7 (2013), 982–1018.
Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. American Journal of Gastroenterology 110 (2015), 1324–1338.
Schoepfer, A.M., Beglinger, C., Straumann, A., et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflammatory Bowel Diseases 19 (2013), 332–341.
D'Haens, G., Ferrante, M., Vermeire, S., et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflammatory Bowel Diseases 18 (2012), 2218–2224.
Guardiola, J., Lobaton, T., Rodriguez-Alonso, L., et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clinical Gastroenterology and Hepatology 12 (2014), 1865–1870.
Lin, J.F., Chen, J.M., Zuo, J.H., et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflammatory Bowel Diseases 20 (2014), 1407–1415.
Buisson, A., Gonzalez, F., Poullenot, F., et al. Patients’ point of view regarding acceptability and usefulness of inflammatory bowel disease monitoring tools: results from a nationwide multicentre study (the ACCEPT study). Gastroenterology, 150, 2016, s984.
Hessels, J., Douw, G., Yildirim, D.D., et al. Evaluation of prevent ID and quantum blue rapid tests for fecal calprotectin. Clinical Chemistry and Laboratory Medicine 50 (2012), 1079–1082.
Vinding, K.K., Elsberg, H., Munkholm, P., et al. Fecal calprotectin measured by patients at home using smartphones- a new clinical tool in monitoring patients with inflammatory bowel disease. Inflammatory Bowel Diseases 22 (2016), 336–344.
Elkjaer, M., Burisch, J., Voxen Hansen, V., et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Alimentary Pharmacology Therapeutics 31 (2010), 323–330.
Weber, J., Ueberschlag, M.E., Prica, M., et al. Validation of a smartphone-based patient monitoring system measuring calprotectin as the therapy follow-up marker. Journal of Crohn's and Colitis 1:S9 (2015), S212–S213.
Pedersen, N., Elkjaer, M., Duricova, D., et al. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease. Alimentary Pharmacology Therapeutics 36 (2012), 840–849.
Harvey, R.F., Bradshaw, J.M., A simple index of Crohn's disease activity. The Lancet, 1, 1980, 514.
Walsh, A.J., Ghoch, A., Brain, A.O., et al. Comparing disease activity indices in ulcerative colitis. Journal of Crohn's and Colitis 8 (2014), 318–325.
Brooke, J., SUS: a retrospective. The Journal of Usability Studies 8 (2013), 29–40.
Kristensen, V., Malmstrøm, G.H., Skar, V., et al. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scandinavian Journal of Gastroenterology 51 (2016), 548–555.
Lasson, A., Stotzer, P.O., Öhman, L., et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. Journal of Crohn's and Colitis 9 (2015), 26–32.
Riley, J.P., Gabe, J.P., Cowie, M.R., Does telemonitoring in heart failure empower patients for self-care? A qualitative study. Journal of Clinical Nursing 22 (2013), 2444–2455.
Cook, P.F., Emiliozzi, S., El-Hajj, E., et al. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. Patient Education and Counseling 81 (2010), 182–186.
Solomon, M.R., Information technology to support self-management in chronic care: a systematic review. Disease Management & Health Outcomes 16 (2008), 391–401.
Ong, W.M., Chua, S.S., Ng, C.J., Barriers and facilitators to self-monitoring of blood glucose in people with type 2 diabetes using insulin: a qualitative study. Patient Preference and Adherence 8 (2014), 237–246.
Bangor, A., Kotum, P., Miller, J., Determining what individual SUS scores mean: adding an adjective rating scale. The Journal of Usability Studies, 4, 2009 114–112.
